1. Clinical trial of neuroEPO in mild‐to‐moderate Alzheimer's disease. (31st December 2021) Authors: Pérez, Leslie; Sosa, Saily; Valenzuela, Carmen; Bringas, Giosmany; Urrutia, Nelky; Peñalver, Ana Ibis; Dalmau, Evelio; Fernández, Ana; Obaya, Teresita Rodriguez Journal: Alzheimer's & dementia Issue: Volume 17(2021)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ganglioside containing nano-proteoliposome dampens myeloid-derived suppressor cells function and ability to cross-present tumor antigens: a new approach to recover CTL function on tumor bearing individuals. (7th November 2013) Authors: Fernández, Audry; Oliver, Liliana; Rábade-Chediak, Maura; Alvarez, Rydell; Hernández, Arletty; Pérez, Leslie; Fernández, Luis E; Mesa, Circe Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. NeuroEPO in mild‐to‐moderate Alzheimer's disease: Human/Human trials: Cognitive enhancement. (7th December 2020) Authors: Pérez, Leslie; Sosa, Saily; Bringas, Giosmany; López, Danay; Valenzuela, Carmen; Peñalver, Ana Ivis; Dalmau, Evelio; Rodríguez, Teresita; Urrutia, Nelky Journal: Alzheimer's & dementia Issue: Volume 16(2020)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗